количество зарегистрированных пользователей: 69612

Rumedo Медицинский образовательный портал

МЕДИЦИНСКИЙ ОБРАЗОВАТЕЛЬНЫЙ ПОРТАЛ

Академия инновационного образования

БИБЛИОТЕКА

По категориям

По специальностям

  • Зарубежные материалы

    High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes

    Дата публикации 22.10.2020
    Автор: L. J. M. Boonman-de Winter & F. H. Rutten & M. J. M. Cramer & M. J. Landman & A. H. Liem & G. E. H. M. Rutten & A. W. Hoes

    Aims/hypothesis The aim of this study was to assess the prevalence of (unknown) heart failure and left ventricular dysfunction in older patients with type 2 diabetes.

    Подробнее

    1245

  • Зарубежные материалы

    Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial

    Дата публикации 22.10.2020
    Автор: Richard I. G. Holt, Rebecca Gossage-Worrall, Daniel Hind, Michael J. Bradburn, Paul McCrone, Tiyi Morris, Charlotte Edwardson, Katharine Barnard, Marian E. Carey, Melanie J. Davies, Chris M. Dickens, Yvonne Doherty, Angela Etherington, Paul French, Fiona Gaughran, Kathryn E. Greenwood, Sridevi Kalidindi, Kamlesh Khunti, Richard Laugharne, John Pendlebury, Shanaya Rathod, David Saxon, David Shiers, Najma Siddiqi, Elizabeth A. Swaby, Glenn Waller and Stephen Wright on behalf of the STEPWISE Research Group*

    People with schizophrenia die 10–20 years earlier than the general population, with approximately 75% of deaths resulting from physical illness.1 The twofold increased prevalence of overweight and obesity contributes to this excess mortality.2 Some, but not all, studies suggest that dietary

    Подробнее

    917

  • Зарубежные материалы

    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Bruce Neal, M.B., Ch.B., Ph.D., Vlado Perkovic, M.B., B.S., Ph.D., Kenneth W. Mahaffey, M.D., Dick de Zeeuw, M.D., Ph.D., Greg Fulcher, M.D., Ngozi Erondu, M.D., Ph.D., Wayne Shaw, D.S.L., Gordon Law, Ph.D., Mehul Desai, M.D., and David R. Matthews, D.Phil., B.M., B.Ch., for the CANVAS Program Collaborative Group

    Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes.

    Подробнее

    1173

  • Зарубежные материалы

    Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Bernard Zinman, M.D., Christoph Wanner, M.D., John M. Lachin, Sc.D., David Fitchett, M.D., Erich Bluhmki, Ph.D., Stefan Hantel, Ph.D., Michaela Mattheus, Dipl. Biomath., Theresa Devins, Dr.P.H., Odd Erik Johansen, M.D., Ph.D., Hans J. Woerle, M.D., Uli C. Broedl, M.D., and Silvio E. Inzucchi, M.D., for the EMPA-REG OUTCOME Investigators

    The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

    Подробнее

    1134

  • Зарубежные материалы

    Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

    Дата публикации 22.10.2020
    Автор: Iciar Martín-Timón, Cristina Sevillano-Collantes, Amparo Segura-Galindo, Francisco Javier del Cañizo-Gómez

    Diabetes mellitus is a chronic condition that occurs when the body cannot produce enough or effectively use of insulin. Compared with individuals without diabetes, patients with type 2 diabetes mellitus have a considerably higher risk of cardiovascular morbidity and mortality, and are disproportionately affected by cardiovascular disease.

    Подробнее

    1186

  • Зарубежные материалы

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (The new england journal of medicine)

    Дата публикации 22.10.2020
    Автор: Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown-Frandsen, M.D., Peter Kristensen, M.D., E.M.B.A., Johannes F.E. Mann, M.D., Michael A. Nauck, M.D., Steven E. Nissen, M.D., Stuart Pocock, Ph.D., Neil R. Poulter, F.Med.Sci., Lasse S. Ravn, M.D., Ph.D., William M. Steinberg, M.D., Mette Stockner, M.D., Bernard Zinman, M.D., Richard M. Bergenstal, M.D., and John B. Buse, M.D., Ph.D., for the LEADER Steering Committee on behalf of the LEADER Trial Investigators

    The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

    Подробнее

    933

  • Зарубежные материалы

    Prevalence of Low Glomerular Filtration Rate in Nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III)

    Дата публикации 22.10.2020
    Автор: Department of Medicine, McMaster University, Hamilton, Ontario; Department of Medicine, University of Western Ontario, London, Ontario; Health Research Methodology Graduate Program, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario; and Department of Medicine, Dalhousie University, Halifax, Nova Scotia

    End-stage renal disease is an important and costly health problem. Strategies for its prevention are urgently needed. Knowledge of the population-based prevalence of renal insufficiency in nondiabetic adults would inform such strategies.

    Подробнее

    1002

  • Статьи

    Инициация терапии сахарного диабета 2 типа: новые возможности

    Дата публикации 22.10.2020
    Автор: А.М. Мкртумян, д.м.н., проф.

    В настоящее время сахарный диабет (СД) 2 типа является глобальной проблемой здравоохранения – распространенность патологии достигла масштабов эпидемии как в развитых, так и развивающихся странах

    Подробнее

    1054

  • Зарубежные материалы

    Cardiorenal Syndrome

    Дата публикации 22.10.2020
    Автор: Claudio Ronco, MD, Mikko Haapio, MD, Andrew A. House, MSC, MD, Nagesh Anavekar, MD, Rinaldo Bellomo, MD

    The term cardiorenal syndrome (CRS) increasingly has been used without a consistent or well-accepted definition. To include the vast array of interrelated derangements, and to stress the bidirectional nature of heartkidney interactions, we present a new classification of the CRS with 5 subtypes that reflect the pathophysiology, the time-frame, and the nature of concomitant cardiac and renal dysfun ...

    Подробнее

    1159

  • Зарубежные материалы

    Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

    Дата публикации 22.10.2020
    Автор: E.A. Bohula, S.D. Wiviott, D.K. McGuire, S.E. Inzucchi, J. Kuder, K.A. Im, C.L. Fanola, A. Qamar, C. Brown, A. Budaj, A. Garcia‑Castillo, M. Gupta, L.A. Leiter, N.J. Weissman, H.D. White, T. Patel, B. Francis, W. Miao, C. Perdomo, S. Dhadda, M.P. Bonaca, C.T. Ruff, A.C. Keech, S.R. Smith, M.S. Sabatine, and B.M. Scirica, for the CAMELLIA–TIMI 61 Steering Committee and Investigators

    Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined.

    Подробнее

    1027

  • Зарубежные материалы

    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Steven P. Marso, M.D., Stephen C. Bain, M.D., Agostino Consoli, M.D., Freddy G. Eliaschewitz, M.D., Esteban Jódar, M.D., Lawrence A. Leiter, M.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Julio Rosenstock, M.D., Jochen Seufert, M.D., Ph.D., Mark L. Warren, M.D., Vincent Woo, M.D., Oluf Hansen, M.Sc., Anders G. Holst, M.D., Ph.D., Jonas Pettersson, M.D., Ph.D., and Tina Vilsbøll, M.D., D.M.Sc., for the SUSTAIN-6 Investigators

    Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown.

    Подробнее

    1039

  • Статьи

    Диагностика хронической сердечной недостаточности с использованием ультразвукового исследования сердца: все ли мы применяем в практической деятельности?

    Дата публикации 22.10.2020
    Автор: Ю. С. Малов, А. Г. Обрезан, М. М. Косарев

    Хроническая сердечная недостаточность (ХСН) является признанным конечным этапом прогрессирования сердечно-сосудистой патологии. Не переходя к рассуждению о том, что представляет собой ХСН (самостоятельную нозологию или осложнение любого хронического сердечного заболевания или, что более верно отражает сущность гемодинамических нарушений — недостаточность кровообращения (НК) или сердечная недостато ...

    Подробнее

    1668

  • Зарубежные материалы

    Kidney Disease as a Risk Factor for Development of Cardiovascular Disease

    Дата публикации 22.10.2020
    Автор: Mark J. Sarnak, MD, Cochair; Andrew S. Levey, MD, Cochair; Anton C. Schoolwerth, MD, Cochair; Josef Coresh, MD, PhD; Bruce Culleton, MD; L. Lee Hamm, MD; Peter A. McCullough, MD, MPH; Bertram L. Kasiske, MD; Ellie Kelepouris, MD; Michael J. Klag, MD, MPH; Patrick Parfrey, MD; Marc Pfeffer, MD, PhD; Leopoldo Raij, MD; David J. Spinosa, MD; Peter W. Wilson, MD

    A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention

    Подробнее

    1339

  • Статьи

    Особенности почечной патологии у больных сахарным диабетом 2 типа

    Дата публикации 22.10.2020
    Автор: М.Ш. Шамхалова, Н.П. Трубицына, Н.В. Зайцева, М.В. Шестакова

    Сахарный диабет [СД] 2 типа относится к числу наиболее распространенных заболеваний.

    Подробнее

    1084

  • Зарубежные материалы

    Obesity and Diabetic Kidney Disease

    Дата публикации 22.10.2020
    Автор: Christine Maric-Bilkan, PhD. Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA

    The prevalence of obesity (body mass index, BMI ≥ 30 kg/m2) has risen to epidemic proportions and continues to be a major health problem worldwide 1–3. The high prevalence of obesity is closely linked to the increased incidence of a number of chronic diseases, including type 2 diabetes, hypertension and cardiovascular disease 2, 4–8.

    Подробнее

    1532